A series of imidazopyridines substituted with a critical oxazolidinone moiety were identified as inhibitors of the HCV replicon system and exhibited nM Kd's for binding to purified NS4B protein.  Despite excellent potencies, these oxazolidinones suffered from poor dose escalation and a high CYP liability.  Optimization of this series provided the discovery of a piperazinone subseries which afforded improvements in both potency and PK and provided a potential development candidate.

Design and synthesis of imidazopyridine compounds as potent HCV antiviral agents

243rd National Meeting (2012)

The official archive and repository for all ACS Meetings & Expositions abstracts and select posters or presentations.